European Association for the Study of Obesity Apr 17 2025 New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide). The study is by Nadja Auerbach, Voy*, London, UK and Dr Austen El-Osta, Director of the Self-Care Academic Research Unit (SCARU) at the School of Public Health, Imperial College